X4 Pharmaceuticals Ownership | Who Owns X4 Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

X4 Pharmaceuticals Ownership Summary


X4 Pharmaceuticals is owned by 14.54% institutional investors, 1.27% insiders, and 84.20% retail investors. Bain capital life sciences investors is the largest institutional shareholder, holding 8.42% of XFOR shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.90% of its assets in X4 Pharmaceuticals shares.

XFOR Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockX4 Pharmaceuticals14.54%1.27%84.20%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bain capital life sciences investors16.92M8.42%$12.41M
Nea management company14.99M7.46%$10.99M
Blackrock funding, inc. /de11.06M5.51%$8.11M
Blackrock10.68M5.34%$6.19M
Vanguard group8.20M4.08%$6.02M
Orbimed advisors7.13M3.55%$5.23M
Kingdon capital management4.94M2.46%$3.62M
Geode capital management3.50M1.74%$2.57M
Axa3.07M1.53%$2.25M
State street2.76M1.38%$1.60M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bain capital life sciences investors16.92M1.46%$12.41M
Nea management company14.99M0.62%$10.99M
Kingdon capital management4.94M0.52%$3.62M
Pale fire capital se1.40M0.23%$1.03M
Orbimed advisors7.13M0.11%$5.23M
Ubs oconnor1.26M0.07%$928.04K
Gsa capital partners llp1.27M0.07%$934.00K
Knott david m jr154.07K0.04%$113.03K
Axa3.07M0.01%$2.25M
Schonfeld strategic advisors1.39M0.01%$1.02M

Top Buyers

HolderShares% AssetsChange
Blackrock10.68M0.00%1.94M
Susquehanna group, llp1.89M0.00%1.71M
Gsa capital partners llp1.27M0.07%765.94K
Group one trading797.41K0.00%671.91K
Ubs group923.06K0.00%661.93K

Top Sellers

HolderShares% AssetsChange
Adage capital partners gp---4.28M
Soleus capital management---4.05M
Perceptive advisors---3.55M
Avidity partners management lp---2.41M
Sio capital management---1.30M

New Positions

HolderShares% AssetsChangeValue
Atria wealth solutions60.00K0.00%60.00K$44.02K
Cantor fitzgerald, l. p.40.25K0.00%40.25K$29.53K
Wolverine trading39.66K-39.66K$32.05K
Integrated wealth concepts30.00K0.00%30.00K$22.01K
Colony group25.02K-25.02K$18.36K

Sold Out

HolderChange
Headlands-16.00
Nelson, van denburg & campbell wealth management group-22.00
Advisor group-400.00
Cubist systematic strategies-469.00
True wealth design-486.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202451-50.00%29,200,759-70.97%140.58%18-61.70%12-36.84%
Sep 30, 2024102-2.86%100,589,648-0.93%501.94%47-16.07%195.56%
Jun 30, 20241051.94%101,538,962-1.42%501.51%5643.59%18-28.00%
Mar 31, 20241037.29%103,000,3366.45%572.40%39-13.33%2531.58%
Dec 31, 202396-96,763,239-13.91%491.11%4528.57%19-29.63%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF5.03M2.90%1.00
Vanguard Total Stock Mkt Idx Inv4.77M2.79%-
iShares Russell 2000 ETF4.80M2.76%-41.58K
UTM IM GBP AXA Framlington Biotech2.95M1.73%-
Vanguard Institutional Extnd Mkt Idx Tr1.94M1.13%-
MEDICAL BioHealth EUR Acc1.78M1.06%-
Fidelity Small Cap Index1.71M0.98%-31.93K
iShares Russell 2000 Growth ETF1.44M0.83%-6.84K
State St Russell Sm/Mid Cp® Indx NL Cl C1.00M0.59%-
State St Russell Sm/Mid Cp® Indx SL Cl I1.00M0.58%-

Recent Insider Transactions


DateNameRoleActivityValue
May 17, 2024Baldry Mark Chief Commercial OfficerBuy$14.65K
Nov 15, 2024Baldry Mark Chief Commercial OfficerBuy$4.60K
Jan 24, 2025Ragan Paula President and CEOSell$34.72K
Jan 24, 2025Mostafa Adam S. Chief Financial OfficerSell$33.95K
Jan 24, 2025Baldry Mark Chief Commercial OfficerSell$13.24K

Insider Transactions Trends


DateBuySell
2025 Q1-5
2024 Q417
2024 Q3-1
2024 Q2--
2024 Q1-8

XFOR Ownership FAQ


Who Owns X4 Pharmaceuticals?

X4 Pharmaceuticals shareholders are primarily institutional investors at 14.54%, followed by 1.27% insiders and 84.19% retail investors. The average institutional ownership in X4 Pharmaceuticals's industry, Biotech Stocks , is 68.48%, which X4 Pharmaceuticals falls below.

Who owns the most shares of X4 Pharmaceuticals?

X4 Pharmaceuticals’s largest shareholders are Bain capital life sciences investors (16.92M shares, 8.42%), Nea management company (14.99M shares, 7.46%), and Blackrock funding, inc. /de (11.06M shares, 5.51%). Together, they hold 21.39% of X4 Pharmaceuticals’s total shares outstanding.

Does Blackrock own X4 Pharmaceuticals?

Yes, BlackRock owns 5.34% of X4 Pharmaceuticals, totaling 10.68M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 6.19M$. In the last quarter, BlackRock increased its holdings by 1.94M shares, a 22.21% change.

Who is X4 Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Bain capital life sciences investors is X4 Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 1.46% of its assets in 16.92M X4 Pharmaceuticals shares, valued at 12.41M$.

Who is the top mutual fund holder of X4 Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of X4 Pharmaceuticals shares, with 2.90% of its total shares outstanding invested in 5.03M X4 Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools